← NewsAll
Immunic presents new CALLIPER phase 2 data on vidofludimus calcium at ACTRIMS 2026
Summary
Immunic will present additional phase 2 CALLIPER trial data on vidofludimus calcium at the ACTRIMS Forum 2026; the company reports MRI analyses showing reductions in several lesion measures and a subset analysis showing declines in EBV‑specific T‑cell receptor sequences versus placebo.
Content
Immunic announced it will present additional data from the phase 2 CALLIPER trial of vidofludimus calcium at the ACTRIMS Forum 2026, with two posters scheduled for February 5. The company describes the trial population as patients with progressive multiple sclerosis and highlights MRI and antiviral immune analyses. Posters will be accessible on Immunic’s website and company staff will be available at booth N9 during the meeting. The article also notes ongoing late‑stage development work and referenced timing for future milestones.
Key findings:
- Immunic said two poster presentations will be presented at ACTRIMS Forum 2026 (Feb 5) reporting additional CALLIPER phase 2 data on vidofludimus calcium.
- Reported MRI results include declines in the proportion of patients with gadolinium‑enhancing lesions over time and statistically significant differences in mean T2 lesion volume at weeks 48, 72 and 96, plus a reported difference in slowly expanding lesions at week 96 versus placebo.
- In a subset of 87 trial participants, the article reports a progressive decline in EBV‑specific T‑cell receptor matches in the vidofludimus calcium group compared with stable levels in placebo (reported p=0.0004), while influenza A–related matches showed no significant change.
Summary:
The article reports that Immunic will present additional CALLIPER phase 2 analyses at ACTRIMS and that those analyses, as described by the company, include MRI markers and antiviral immune measures. Posters will be presented at the February 5 session and made available on the company’s website; the company also notes ongoing phase 3 work and an expected timeline for later data reporting. Undetermined at this time.